You are here

Shire Signs Deal to Develop a New Way to Administer Hemophilia Drug

New technology would allow oral dosing of drugs typically administered by injection

Shire PLC is partnering with a California-based company to develop a new way to administer a drug to treat hemophilia A, according to reporting by Reuters. The company, Rani Therapeutics, has developed a technology that will help oral delivery of peptides, proteins, and therapeutic antibodies that to date could be delivered only through injections.

Once delivered through Rani Pill—the oral delivery technology—the drug stays in the body until it enters the small intestine and the medicine is transferred into the intestinal wall, the companies said. The method does not expose the medication to digestive enzymes and is also expected to be pain free, since the intestines do not have sharp pain receptors, the companies said.

Shire, which made an equity investment in Rani, has the option to negotiate a licensing deal to develop and market the drug delivery approach, after completion of certain studies.

Hemophilia is a chronic disease that causes longer-than-normal bleeding due to absent or deficient clotting factor in the blood.

Source: Reuters; December 5, 2017.

More Headlines

Study shows improved performance for FluMist quadrivalent vaccine
Patients take oral GLP-1 analogue as a single daily tablet
Lancet publishes meta-analysis pooling almost 120,000 patients
Two out of three women achieve a clinical response
Nearly 68% of patients treated with AR101 could tolerate peanut protein
Tablets are also indicated to treat drug-induced extrapyramidal reactions
But lawmakers are far from united on the issue
New CEO believes “breakthrough innovations” are key to future growth
Law journal article considers the strategy’s legal and ethical implications